Caroline J. Springer
About
In The Last Decade
Caroline J. Springer
126 papers receiving 8.6k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Molecular Biology 6.6k
- Oncology 3.1k
- Genetics 1.3k
- Organic Chemistry 1.1k
- Computational Theory and Mathematics 944
Countries citing papers authored by Caroline J. Springer
This map shows the geographic impact of Caroline J. Springer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline J. Springer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline J. Springer more than expected).
Fields of papers citing papers by Caroline J. Springer
This network shows the impact of papers produced by Caroline J. Springer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline J. Springer. The network helps show where Caroline J. Springer may publish in the future.
Co-authorship network of co-authors of Caroline J. Springer
This figure shows the co-authorship network connecting the top 25 collaborators of Caroline J. Springer. A scholar is included among the top collaborators of Caroline J. Springer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline J. Springer. Caroline J. Springer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 43 | |
| 2 | 73 | |
| 3 | 38 | |
| 4 | 51 | |
| 5 | 272 | |
| 6 | 58 | |
| 7 | 15 | |
| 8 | Evidence of efficacy of antibody directed enzyme prodrug therapy (ADEPT) in a Phase I trial in patients with advanced carcinoma. | 2 |
| 9 | 241 | |
| 10 | 11 | |
| 11 | 3 | |
| 12 | 13 | |
| 13 | 360 | |
| 14 | 166 | |
| 15 | Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954 | 2 |
| 16 | 51 | |
| 17 | 108 | |
| 18 | Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. | 56 |
| 19 | 16 | |
| 20 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.